Pharmability has received regulatory approval from the Swedish Medical Products Agency to initiate a Phase Ib clinical trial for its lead candidate, TIR-C, targeting atopic dermatitis. This first-in-human study, to be conducted in Sweden, is designed to evaluate the safety and tolerability of the peptide drug while also exploring early efficacy signals. The transition to clinical testing marks a significant milestone for the company after several years of preclinical development.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.